Cytokinetics Publishes Phase II Evidence Of Effect Study Of CK-2017357

6/12/2012 7:48 AM ET

Cytokinetics, Inc. (CYTK: Quote) announced the publication of its Phase II Evidence of Effect clinical study of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis, or ALS.

The results showed that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS that were studied. In addition, measures of muscle endurance appeared to be improved in a dose-related fashion in patients who received CK-2017357. Also, patients who received CK-2017357, and their investigators, perceived a global benefit on treatment.

The company noted that data from the study, which compared single doses of CK-2017357 to placebo, informed the design of subsequent studies conducted by it which have assessed the safety and tolerability of CK-2017357 in other dosing regimens.

Click here to receive FREE breaking news email alerts for Cytokinetics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 123 Articles

Editors Pick

HP Profit Falls Yet Tops Estimates

Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast.

Worries About Fed Tapering Lead To Sell-Off On Wall Street - U.S. Commentary

Stocks showed a substantial downturn over the course of the trading day on Wednesday after seeing some strength in morning trading. Renewed worries about the Federal Reserve tapering its asset purchase program contributed to the sharp pullback by the markets. The major averages climbed off their worst levels going into the close but still ended the day firmly negative.

Fed Minutes Show Some Members Want To Scale Back QE3 This Summer

Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...